The Comparative Efficacy and Safety of Entecavir and Lamivudine in Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis
Table 4
Efficacy comparison of entecavir and lamivudine for continuous outcomes.
Outcome of interest
Number of studies
Sample size
Effect estimate
Heterogeneity
Entecavir
Lamivudine
MD (95% CI)
value
(%)
value
TBIL level
1 month
3
134
126
−12.43 (−36.43, 11.58)
0.31
0
0.42
3 months
3
236
229
−1.69 (−6.66, 3.29)
0.51
0
0.82
12 months
3
215
201
−8.73 (−12.74, −4.72)
<0.0001
0
0.73
ALT level
1 month
4
303
286
−4.96 (−10.07, 0.14)
0.06
0
0.64
12 months
3
215
201
−3.08 (−6.08, −0.07)
0.04
0
0.68
PTA level
1 month
4
283
274
2.12 (0.42, 3.82)
0.01
21%
0.29
3 months
3
236
229
1.91 (−1.33, 5.15)
0.25
0
0.76
12 months
3
215
201
3.6 (−1.07, 8.26)
0.13
0
0.99
TBIL: total bilirubin; ALT: alanine aminotransferase; PTA: prothrombin activity; MD: mean difference; CI: confidence interval.
